

Bod Australia Limited (ASX:BDA) is a developer, distributor and marketer of health products and supplements, with a focus on plant-based extracts including medicinal cannabis.

#### CAPITAL STRUCTURE

ASX code	<b>BDA</b>
Shares on issue	88.7m
Market Capitalisation	~\$29.4m

#### BOARD & MANAGEMENT

Mr George Livery  
Executive Chairman

Ms Jo Patterson  
Chief Executive Officer

Mr Stephen Thompson  
Executive Director

Mr Akash Bedi  
Non-Executive Director

Mr Patrice Malard  
Non-Executive Director

Mr Simon O'Loughlin  
Non-Executive Director

Mr Simon Taylor  
Non-Executive Director

Mr Stephen Kelly  
Company Secretary

#### CONTACT

Level 1, 377 New South Head Rd  
Double Bay, NSW 2028

## Bod to take part in Europe's largest medicinal cannabis project targeting 20,000 patients

- Invited to become 1 of 5 companies for Project Twenty21 study targeting 20,000 patients
- Facilitates Bod's entry into UK medicinal cannabis market in the near term
- Payment will be received for each prescription filled - Company expecting to prescribe a minimum of 1,000 patients
- MediCabilis™ prescription volumes growing domestically - 1,713 prescriptions filled YTD

**Sydney, Australia – 8 November 2019:** Medicinal cannabis healthcare products company, Bod Australia Limited ("Bod", the "Company") (ASX: BDA), will be participating in Project Twenty21, Europe's largest medicinal cannabis project, which will study the effects of cannabis when used on patients with chronic conditions.

Project Twenty21 is a UK based study which will enrol 20,000 patients by the end of 2021 to create the largest body of evidence for the efficacy of medicinal cannabis. The aim is to utilise collated data to convince policy makers that medicinal cannabis should be made more readily available, and affordable, for patients who would benefit from it across the UK. Further, the project aims to assist prescribers operating in the region and advance the potential for NHS funding.

The project will follow 20,000 patients with a range of conditions, including chronic pain, Epilepsy, Multiple Sclerosis, Post Traumatic Stress (PTSD), Tourette's Syndrome, anxiety disorders and individuals dealing with harm of substance abuse.

Bod is one of five companies invited to participate in Project Twenty21 and is aiming to treat a minimum of 1,000 patients with its MediCabilis™ CBD product ("MediCabilis™"). The Company will receive a cost per prescription for each MediCabilis™ unit sold. Bod also has the ability to introduce additional products to patients undertaking the study as they come to market, further underpinning revenue.

The study will build brand awareness for MediCabilis™, credibility, and enhance research data and grow relationships across the UK. The Company is well positioned, as MediCabilis™ has already been used effectively to treat a large number of Australian patients suffering from chronic pain, Epilepsy, Multiple Sclerosis, Post Traumatic Stress (PTSD), Tourette's Syndrome and anxiety disorders.

#### Medicinal Cannabis sales continue domestic growth:

Domestically, prescription volumes for MediCabilis™ remains steady. Throughout October, Bod dispensed 555 MediCabilis™ prescriptions (September: 549). 1,713 prescriptions have now been filled in 2019.

Bod is witnessing continued increases in repeat prescriptions, further reinforcing physician and patient product satisfaction. MediCabilis™ is being prescribed to treat 17 different conditions outlining the adaptability of the product. Bod expects prescription volumes to increase in the coming months, as more clinics across Australia open and begin to prescribe MediCabilis™.




Image one: cumulative increase in prescription volumes

**Management commentary:**

**CEO Jo Patterson said:** “Our participation in Project Twenty21 validates Bod’s position as one of Australia’s leading medicinal cannabis companies. The study provides us with a seamless market entry into the United Kingdom and the opportunity to solidify a footprint ahead of legislative and regulatory changes.

“While prescription volumes remained steady at a domestic level, it was encouraging to witness an ongoing increase in repeat prescriptions and MediCabilis™ being utilised to treat 17 different conditions. We are confident that volumes will increase during November, as more clinics come to market.”

- ENDS -

**ABOUT BOD AUSTRALIA**

**Bod Australia Limited (ASX:BDA)** is a developer, distributor and marketer of health and skincare products. Bod works with plant based extracts, with specific expertise in leveraging the health benefits associated with cannabis and hemp.

Bod is actively developing a range of over-the-counter and prescription products based on its unique, standardised, pharmaceutical grade cannabis extracts.

The Company has a large distribution footprint in Australia, selling prescription and OTC products to over 1,000 retail outlets, including pharmacies, retail stores and healthcare chains. The Company also has distribution agreements with two of Australia’s largest pharmacy wholesalers providing it with access to over two thirds of the market. Bod is also actively building capability in key European markets that it witnesses near term growth prospects.

**BODAUSTRALIA.COM**

**For more information please contact:**

Jo Patterson  
Chief Executive Officer  
[info@bodaustralia.com](mailto:info@bodaustralia.com)  
+61 2 9199 5018

Henry Jordan  
Six Degrees Investor Relations  
[henry.jordan@sdir.com.au](mailto:henry.jordan@sdir.com.au)  
+61 431 271 538

For personal use only

